Before their exocytotic release during stimulation of nerve terminals, nonpeptide neurotransmitters are loaded into synaptic vesicles by specific transporters. Recently, a protein initially identified as brain-specific Na ϩ -dependent inorganic phosphate transporter I (BNPI) has been shown to represent a vesicular glutamate transporter (VGLUT1). In this study, we investigated whether a highly homologous "differentiationassociated Na ϩ -dependent inorganic phosphate transporter" (DNPI) is involved in glutamatergic transmission. Vesicles isolated from BON cells expressing recombinant DNPI accumulated L-glutamate with bioenergetical and pharmacological characteristics identical to those displayed by VGLUT1 and by brain synaptic vesicles. Moreover, DNPI localized to synaptic vesicles, at synapses exhibiting classical excitatory features. DNPI thus represents a novel vesicular glutamate transporter (VGLUT2). The distributions of each VGLUT transcript in brain were highly complementary, with only a partial regional and cellular overlap. At the protein level, we could only detect either VGLUT1-or VGLUT2-expressing presynaptic boutons. The existence of two VGLUTs thus defines distinct subsets of glutamatergic neurons.
Before their exocytotic release during stimulation of nerve terminals, nonpeptide neurotransmitters are loaded into synaptic vesicles by specific transporters. Recently, a protein initially identified as brain-specific Na ϩ -dependent inorganic phosphate transporter I (BNPI) has been shown to represent a vesicular glutamate transporter (VGLUT1). In this study, we investigated whether a highly homologous "differentiationassociated Na ϩ -dependent inorganic phosphate transporter" (DNPI) is involved in glutamatergic transmission. Vesicles isolated from BON cells expressing recombinant DNPI accumulated L-glutamate with bioenergetical and pharmacological characteristics identical to those displayed by VGLUT1 and by brain synaptic vesicles. Moreover, DNPI localized to synaptic vesicles, at synapses exhibiting classical excitatory features. DNPI thus represents a novel vesicular glutamate transporter (VGLUT2). The distributions of each VGLUT transcript in brain were highly complementary, with only a partial regional and cellular overlap. At the protein level, we could only detect either VGLUT1-or VGLUT2-expressing presynaptic boutons. The existence of two VGLUTs thus defines distinct subsets of glutamatergic neurons.
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Nonpeptide neurotransmitters are stored into synaptic vesicles by specific transporters driven by a V-type H ϩ -ATPase (Gasnier, 2000) . Two recent studies have identified a transporter responsible for the vesicular storage of glutamate (Bellocchio et al., 2000; Takamori et al., 2000) , the major excitatory transmitter of mammalian CNS. Surprisingly, this protein was initially described as a brain-specific Na ϩ -dependent inorganic phosphate (Pi) transporter I (BNPI) based on its induction of an Na ϩ /Pi cotransport when expressed in Xenopus oocytes (Ni et al., 1994) . However, an impressive set of data now advocates a role in the filling of glutamatergic vesicles. First, EAT-4, a Caenorhabditis elegans homolog of BNPI, is specifically involved in glutamatergic neurotransmission at the presynaptic level (Dent et al., 1997; Lee et al., 1999) . Second, BNPI localizes to a subset of glutamatergic synaptic vesicles (Bellocchio et al., 1998) . Third, the expression of BNPI in neuroendocrine cells induces a glutamate uptake activity that shares all of the characteristics observed on synaptic vesicles (Bellocchio et al., 2000; Takamori et al., 2000) . Fourth, BNPI induces a quantal release of glutamate in a serotoninergic cell line (Takamori et al., 2000) . Last, autaptic GABAergic neurons expressing recombinant BNPI display an additional glutamatergic response (Takamori et al., 2000) . BNPI is thus not only necessary but is sufficient for the exocytotic release of glutamate. Accordingly, the protein was renamed VGLUT1 (vesicular glutamate transporter 1).
VGLUT1 belongs to the type 1 family of Na ϩ /Pi cotransporters (Werner et al., 1998) . A "differentiation-associated Na ϩ -dependent inorganic phosphate transporter" (DNPI) that is upregulated during the differentiation of rat pancreatic AR42J cells into neuron-like cells was described recently in this family (Aihara et al., 2000) . Interestingly, DNPI is highly homologous to VGLUT1 (82% amino acid identity), and its transcript is abundant in brain regions that apparently lack VGLUT1 mRNA. Moreover, DNPI mRNA localizes to neurons . Recent studies have established a vesicular localization of DNPI in excitatory neurons (Fujiyama et al., 2001; Sakata-Haga et al., 2001) . We thus decided to examine the hypothesis that DNPI might represent a novel vesicular glutamate transporter.
MATERIALS AND METHODS
cDNA cloning and e xpression. The DN PI f ull-length clone was obtained by screening a Z ap II hippocampus cDNA library (Stratagene, La Jolla, CA) with a probe derived from the published sequence (nucleotides 356 -924) (Aihara et al., 2000) . This resulted in the isolation of a 3000 bp cDNA insert in pBluescript. VGLUT1 was isolated by reverse transcription (RT)-PCR amplification of total rat brain RNA using the access system (Promega, Madison, W I) with primers 5Ј-GGCACAGCCC -ACCATGGAGTTC -3Ј (forward) and 5Ј-TGAGGCAGGAGAGGAG-TGGG-3Ј (reverse) and total rat brain RNA. The PCR product was cloned into pCRII-Topo (Invitrogen, San Diego, CA). Both inserts were sequenced and subcloned into the expression vector pcDNA3 (Invitrogen).
The BON cell line (a gift from B. Wiedenmann, Berlin, Germany) was cultured at 37°C under 5% C O 2 in DM EM-nutrient mix F-12 (1:1) (Life Technologies, Gaithersburg, MD), supplemented with 7.5% fetal bovine serum, 100 U/ml penicillin, and 100 mg /ml streptomycin. C ells were transfected by electroporation with pcDNA3 vectors (Invitrogen) bearing the rat DNPI, VGLUT1, or VIAAT (vesicular inhibitory amino acid transporter, also termed VGAT) (E. Herzog, unpublished observation) cDNAs or no insert. Stable transfectants were selected with 800 g/ml G418 (Life Technologies) and screened by immunofluorescence and immunoblotting.
Subcellular f ractionation and amino acid uptak e assay. Synaptosomes and synaptic vesicles were prepared from rat brain cortex by standards methods (Huttner et al., 1983) . BON clones were cultured on 15 cm dishes. For each clone, cells from three confluent dishes (ϳ10 8 cells) were washed with PBS, scraped, and recovered in 10 ml of chilled 0.32 M sucrose and 4 mM H EPES-KOH, pH 7.4. C ells were homogenized using a Bioneb C ell Disruption System (Glas-Col Laboratory Products). A single cycle of nebulization under a 3.3 l /min stream of nitrogen at 2.5 bar was sufficient to break virtually all cells but maintained the latency of an intralysosomal marker (␤-glucuronidase, measured using 4-methylumbelliferyl-␤-D-glucuronide as substrate) at ϳ60%. Nuclei and cell debris were pelleted at 10,000 ϫ g for 5 min, and the resulting supernatant was centrif uged at 200,000 ϫ g for 20 min. The resulting membrane pellet was resuspended in 400 l of ice-cold 0.32 M sucrose, 4 mM KC l, 4 mM MgSO 4 , and 10 mM H EPES-KOH, pH 7.4 (final concentration, 10 mg /ml protein). [
3 H]L-glutamate and [ 3 H]L-aspartate (both from Amersham Pharmacia Biotech, Uppsala, Sweden) uptake assays were performed as described previously (Bellocchio et al., 2000) . Each uptake measurement was performed in triplicate and is expressed as mean Ϯ SEM. E xperiments were independently repeated twice on two different BON-DN PI clones.
Immunoblotting. Anti-VGLUT1 antiserum was obtained by immunizing rabbits (Agro-Bio, Villeny, France) against the peptide CGL APSYG-ATHSTVQPPR coupled via its cysteine residue to keyhole limpet hemocyanin (K L H). For the anti-DN PI serum, rabbits were immunized against the peptide H EDELDEETGDI TQN YI N Y coupled at its N terminus to K L H. Western blots were performed with 5 or 10 g of protein per lane (see Figs. 2 and 3, respectively) . Immunoreactivity was detected with anti-DN PI (1:1000), anti-VGLUT1 (1:3000), or anti-V IAAT (1:5000) (Dumoulin et al., 1999) sera by chemiluminescence.
In situ hybridization. Regional in situ hybridization was performed with antisense [
35 S]dATP-labeled oligonucleotides 5Ј-GCAC TGGGCACA-AGGGAAGAC TTGCATC TT-3Ј and 5Ј-ACAGATTGCAC TTGATG-GGAC TC TCACGGT-3Ј for VGLUT1 and DN PI, respectively, as described previously (Sagne et al., 2001) . Cold in situ hybridization was performed with antisense riboprobes labeled with either fluorescein-UTP (for VGLUT1) or digoxigenin-UTP (for DN PI) (Ravassard et al., 1997) . Colorimetric revelations were obtained with 5-bromo-4-chloro-3-indolyl phosphate (Roche Products, Hertforshire, UK) and either nitroblue tetrazolium (Roche) or 2-[4-iodophenyl]-3-[4-nitrophenyl]-5-phenyl-tetrazolium chloride (Roche) for the blue and red staining, respectively.
Immunoautoradiography. Immunoautoradiography was performed as described previously (Masson et al., 1999) . In brief, sagittal or coronal rat brain sections were fixed with 4% paraformaldehyde and incubated with each antiserum (1:2000 dilution) and then with [
125 I]IgG (0.25 C i /ml; Amersham Pharmacia Biotech). Sections were apposed to x-ray films (␤max; Amersham Pharmacia Biotech) for 5 d.
Immunohistochemistr y. Sprague Dawley rats were deeply anesthetized with sodium chloral hydrate and perf used transcardially with a mixture of 2% paraformaldehyde and 0.2% glutaraldehyde. Frontal sections of the brain were cut on a vibrating microtome at 70 m, collected in PBS, cryoprotected, freeze-thawed, and stored in PBS until use.
VGLUT1 and DN PI were codetected according to an immunofluorescence method that permits the simultaneous detection of two antibodies raised in the same species (Shindler and Roth, 1996) . VGLUT1 antiserum (1:2000) was detected with the tyramide system (TSA) (N EN, Boston, M A). Conventional fluorescently labeled secondary antibodies detected DN PI antiserum (1:3000). For the last step of the experiment, the sections were incubated in a mixture of streptavidin coupled to fluorescein (1:1000; Jackson ImmunoResearch, West Grove, PA) to complete the detection of VGLUT1 by the TSA method and goat anti-rabbit coupled to cyanine-3 (C Y3) (1:200; Jackson ImmunoResearch) to detect DN PI. The sections were mounted in Vectashield (Vector Laboratories, Burlingame, CA) and observed using a confocal microscope (L SM 410; Z eiss, Oberkochen, Germany). The specificity of each labeling was proven by the absence of DN PI or VGLUT1 labeling when the primary or secondary antibody was omitted. An antisynaptophysin monoclonal serum (1:500; Chemicon, Temecula, CA) was used for immunofluorescence codetection of DN PI, VGLUT1, and synaptophysin, visualized with anti-rabbit IgG-C Y3 or anti-mouse IgG-FI TC conjugates (Jackson ImmunoResearch).
VGLUT1 and DN PI were detected at the electron microscopic level using the preembedding immunogold method with silver intensification (Bernard et al., 1999) . After treatment with 1% osmium, dehydration, and embedding in resin, ultrathin sections were cut, stained with lead citrate, and examined using a Philips C M10 EM.
RESULTS

DNPI is a glutamate transporter
To investigate the molecular function of DNPI, the neuroendocrine cell line BON (Evers et al., 1991) was stably transfected with a DNPI expression plasmid. The ability of a membrane fraction enriched in DNPI (data not shown) to accumulate [ 3 H]Lglutamate in the presence of ATP was examined. For comparison, membranes from BON clones expressing VGLUT1 or, as negative controls, VIAAT (McIntire et al., 1997; Sagne et al., 1997) or no cDNA, were analyzed in parallel experiments. Membranes from DNPI-expressing cells (Fig. 1 A) and VGLUT1-expressing cells (data not shown) accumulated twice as much [ 3 H]glutamate than negative controls. [ 3 H]glutamate accumulation was linear over time for 3 min and reached a plateau level at ϳ15 min. As reported for VGLUT1 (Bellocchio et al., 2000; Takamori et al., 2000) , the DNPI-dependent uptake of [ 3 H]glutamate was inhibited by the H ϩ ionophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) (50 M) and by a saturating concentration (5 M) of Evans Blue (Fig. 1 B) , a competitive inhibitor of glutamate uptake into synaptic vesicles (Roseth et al., 1995) . In contrast, the [ 3 H]glutamate uptake activity endogenous to BON cells was insensitive to Evans Blue and only slightly inhibited by CCCP.
To characterize further the bioenergetics of this DNPImediated glutamate transport, several inhibitors were tested. For clarity, results are shown only for the CCCP-sensitive (DNPImediated) component of uptake (Fig. 1C,D) . Bafilomycin A1, a selective inhibitor of the H ϩ -translocating ATPase from acidic organelles, strongly inhibited [ 3 H]glutamate uptake by DNPI, meaning that this uptake is driven by a transmembrane H ϩ electrochemical gradient (⌬H ϩ ). Nigericin, an ionophore that disrupts transmembrane pH gradients by exchanging H ϩ for K ϩ , did not significantly inhibit the uptake (89.1 Ϯ 9.6% of control; mean Ϯ SEM; three independent experiments on two BON clones), suggesting that the translocation of glutamate anions by DNPI is mainly driven by the electrical component of ⌬H ϩ . Indeed, a further addition of the K ϩ ionophore valinomycin, to dissipate the remaining electrical gradient, inhibited [ 3 H]glutamate uptake as efficiently as CCCP. Identical effects were observed for the VGLUT1-mediated glutamate uptake (Fig. 1C) , as reported previously (Bellocchio et al., 2000; Takamori et al., 2000) .
The substrate selectivity of DNPI was assessed by adding 10 mM unlabeled amino acids simultaneously with [ 3 H]glutamate in both the absence and presence of CCCP. Although L-glutamate strongly inhibited DNPI-mediated uptake (11.9 Ϯ 4.5% of control residual activity), activities corresponding to 82 Ϯ 4, 122 Ϯ 4, and 111 Ϯ 0.8% of control were observed in the presence of L-aspartate, L-glutamine, and GABA, respectively (n ϭ 3). Similarly, aspartate, glutamine, and GABA did not significantly inhibit VGLUT1 (data not shown), as reported previously (Bellocchio et al., 2000; Takamori et al., 2000) . The selectivity for glutamate over aspartate was confirmed by the absence of significant [
3 H]L-aspartate accumulation into DNPI-or VGLUT1-containing membranes (data not shown). Incubation of DNPIcontaining membranes with increasing concentrations of [ 3 H]glutamate for 3 min showed that the transport velocity saturates ( Fig. 1 E, F ) , with K M and V max values of 1.9 Ϯ 0.4 mM and 470 Ϯ 110 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 protein, respectively (n ϭ 3). Similarly, values of 3.4 Ϯ 0.9 mM and 500 Ϯ 5 pmol/min protein were obtained for VGLUT1 (n ϭ 2), in agreement with previous observations (Bellocchio et al., 2000) . Evans Blue inhibited VGLUT1-and DNPI-mediated uptakes with similar IC 50 values of ϳ300 nM (data not shown).
Together, these data demonstrate that DNPI is a glutamate transporter that displays functional characteristics very similar, if not identical, to those of VGLUT1. Because DNPI also localizes to synaptic vesicles in brain (see below), the protein is renamed VGLUT2 hereafter.
Regional distribution of VGLUTs
The regional distributions of VGLUT1 and VGLUT2 transcripts were assessed by in situ hybridization. As shown in Figure 2 A, VGLUT1 mRNA is highly enriched in olfactory bulb, cerebral and cerebellar cortices, medial habenula, pontine nucleus (data not shown), and hippocampus (including the subiculum). A lower level of labeling was detected in lateral septum and thalamic nuclei. On the other hand, VGLUT2 transcript is strongly expressed in all thalamus nuclei (except the reticular nucleus), in hypothalamus, inferior and superior colliculi, deep cerebellar nuclei, and many neurons from the brainstem (Fig. 2 B) . Moderate to low levels of VGLUT2 mRNA were observed in hippocampus, some cortical areas, and amygdala (data not shown). These distributions, which are consistent with previous reports (Ni et al., 1995; Hisano et al., 2000) , thus appear mostly complementary. However, a more careful examination of coronal brain sections revealed a regional colocalization in some thalamic nuclei (for example, lateral and medial geniculate, ventral posterior), lateral habenula, septum, and subiculum ( Fig. 2C-H ) . The distribution of VGLUT proteins was examined using polyclonal antisera. Antiserum specificity was first assessed by immunoblotting (Fig. 2 I, J ) . Each antiserum specifically recognized a single diffuse ϳ60 kDa protein in extracts from BON cells expressing VGLUT1 (lane 1) or VGLUT2 (lane 4 ). No crossreactivity was observed (lanes 2, 3) . A single band was also detected by each antiserum in brain extracts (lanes 5, 7 ). These bands disappeared when preimmune serum was used (lane 6, 8) . These results show that our VGLUT1 and VGLUT2 antisera are highly specific, a conclusion further supported by immunofluorescence analysis of transfected BON and COS cells (data not shown).
Immunoautoradiographic analysis using these antisera revealed that most brain areas coexpress both transporters, with a somewhat more laminar pattern for VGLUT2 than for VGLUT1 (Fig. 2 K, L) . This is in complete contrast to the distribution of their cognate transcripts. For example, although no VGLUT2 mRNA was detected in cerebral cortex (Fig. 2 B) , VGLUT2 immunoreactivity was strong in cortical layers IV and VI. These data suggested that the VGLUT2 protein is targeted to nerve terminals of projection neurons, as reported for VGLUT1 (Bellocchio et al., 1998) .
VGLUT2 localizes to synaptic vesicles at excitatory synapses
The intracellular distribution of VGLUT2 was first examined by subcellular fractionation. As shown in Figure 3A , VGLUT2 copurifies with several established markers of synaptic vesicles, such as VGLUT1, VIAAT, and synaptophysin. The association to synaptic vesicles was confirmed by the accumulation of VGLUT2 at nerve terminals. As demonstrated by immunofluorescence microscopy, performed in the striatum, VGLUT2 punctuate labeling colocalizes with synaptophysin (Fig. 3C) . Similar results were observed in all areas inspected (data not shown). The distribution of VGLUT2 was also examined at the ultrastructural level using a preembedding immunogold method. In cortex, cerebellum, and striatum, VGLUT2 immunoparticles accumulated over synaptic vesicle clusters at terminal boutons forming asymmetrical contacts with dendritic shafts or spines (Fig. 3B) . These morphological features are classically displayed by excitatory synapses. No immunoparticles could be detected on symmetric putative GABAergic synapse (data not shown).
Combined biochemical, anatomical, and ultrastructural results strongly suggest that VGLUT2 localizes to synaptic vesicles at excitatory synapses, as does VGLUT1 (Fig. 3) (Bellocchio et al., 1998) . These results are consistent with the conclusions of two recent studies (Fujiyama et al., 2001; Sakata-Haga et al., 2001 ). The expression of VGLUT2 at mossy fiber terminals in the cerebellum, which are established as glutamatergic, further confirmed this conclusion (Fig. 3B, top panel ) .
VGLUT1 and VGLUT2 define distinct subsets of glutamatergic neurons
We then examined whether VGLUT1 and VGLUT2 are coexpressed in glutamatergic neurons and/or nerve endings. This issue was first investigated by in situ hybridization, using colorimetric detection of VGLUT1 and VGLUT2 mRNA probes at the cellular level. Three classes of glutamatergic neuronal cell bodies could be observed, as illustrated for adjacent nuclei in a single section (Fig. 4 A) . VGLUT1-positive neurons (red) were observed in CA3 and in the amygdalo-hippocampal complex. Next, the medial amygdaloid nucleus only expressed the VGLUT2 mRNA (blue). Finally, both messengers were expressed in individual neurons of the lateral olfactory tract (red and blue cells). Additional cases of VGLUT1 and VGLUT2 coexpression were found. For instance, in the thalamus, two populations were present: VGLUT2-positive cells (data not shown) and VGLUT1-VGLUT2-expressing cells (Fig. 4 B, C) .
The possible coexpression of both proteins at individual nerve terminals was also examined by double-immunofluorescence microscopy. However, we were not able to detect "mixed" VGLUT1-VGLUT2-positive terminals in projection areas from these neurons. As illustrated in hippocampus (Fig. 4 D) and cerebral cortex (Fig. 4 E) , VGLUT1 immunoreactivity ( green) never merged with that of VGLUT2 (red).
Together, these data show that the VGLUTs define three subsets of glutamatergic neurons and at least two subsets of glutamatergic terminals. Huttner et al. (1983) . VGLUT2 is enriched in synaptosomes (P2) and synaptic vesicles (LP2). B, Ultrastructural localization of VGLUT2 and VGLUT1. Immunoparticles are detected over synaptic vesicle clusters in axonal terminals ( T) making asymmetrical synaptic contacts (arrows) with dendritic shafts ( d) or spines ( s). Scale bars: B, Cerebellum, 500 nm; B, Cortex, 250 nm. C, Immunofluorescent detection of VGLUT1 or VGLUT2 (both in red) and synaptophysin (in green) are shown in the striatum. VGLUTs puncta colocalizes with synaptophysin ( yellow). Note the low frequency of red puncta. cc, Corpus callosum. Scale bar, 25 m.
DISCUSSION
In this study, we show that a novel member of the type I Na ϩ /Pi cotransporter family, DNPI, is indeed a new vesicular glutamate transporter (VGLUT2). First, the protein biochemically and anatomically localizes to synaptic vesicles (Fig. 3) . Second, VGLUT2 mediates a glutamate uptake activity that is very similar, if not identical, to the activity of native synaptic vesicles or recombinant VGLUT1 (Bellocchio et al., 2000; Takamori et al., 2000) . Finally, VGLUT2 is expressed in a subset of presynaptic excitatory terminals (Fig. 3B) .
Although the two transporters exhibited similar activities, VGLUT1-and VGLUT2-positive neurons displayed strongly different distributions (Fig. 2) , implying that the expression of these two genes is regulated by distinct mechanisms. This was particularly clear when the regional distribution of VGLUT1-and VGLUT2 mRNA was examined. A high complementarity was observed, with only a partial overlap (Fig. 2 A-H ). Investigation at the cellular level confirmed the existence of neurons expressing either VGLUT1 or VGLUT2. However, these experiments also detected an additional subset of neurons that expresses both transcripts (Fig. 4 A-C) . Therefore, the VGLUTs define at least three subsets of glutamatergic neurons, expressing the type 1, the type 2, or both transcripts.
The same analysis was also performed at the level of glutamatergic terminals, by comparing the microscopic distributions of VGLUT1 and VGLUT2 immunoreactivities (Fig. 4 D, E) . However, in this case, only two classes of glutamatergic terminals were found, expressing either the type 1 or the type 2 protein, even in projection areas of regions containing mixed VGLUT1-VGLUT2 mRNA-expressing neurons. Three hypotheses can be proposed at this stage. The most plausible explanation is that we failed to detect colabeled terminals because of their rare occurrence compared with isoform-specific terminals. A second possibility would be that mixed glutamatergic neurons express either the VGLUT1 or the VGLUT2 protein, although both transcripts are present in the soma. Finally, a third provocative alternative would be that both proteins are synthesized in VGLUT1-VGLUT2-positive cells, but an unknown mechanism ensures that they are targeted to distinct terminals within the same neuron.
It must be noted that, although VGLUT1 and VGLUT2 are highly homologous, their amino acid sequences strongly differ at their C termini. In particular, VGLUT1 exhibit proline-rich motifs that are lacking in VGLUT2. Therefore, VGLUT1 and VGLUT2 may interact with distinct sets of associated proteins. This could have important functional consequences at several levels, including protein targeting. The existence of two VGLUTs should thus provide important tools for the anatomical and functional characterization of glutamatergic pathways. 
